convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.47 [0.04, 5.69]< 10%1 study (1/-)72.1 %some concernnot evaluable moderatecrucial-
deaths 0.96 [0.84, 1.10]< 12%8 studies (8/-)73.9 %some concernserious moderatecrucial1
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.48 [0.28, 0.83]< 10%2 studies (2/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.08 [0.87, 1.34]> 10%4 studies (4/-)75.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.27 [0.90, 5.72]> 10%1 study (1/-)95.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.40 [0.85, 2.29]> 10%2 studies (2/-)90.7 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.91, 1.30]> 10%4 studies (4/-)81.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.45 [0.05, 4.34]< 164%2 studies (2/-)75.5 %some concernnot evaluable moderateimportant-
hospital discharge 0.99 [0.92, 1.07]> 10%1 study (1/-)41.3 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.98 [0.88, 1.08]< 10%4 studies (4/-)66.7 %some concernnot evaluable moderateimportant1
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.95 [0.55, 1.64]< 140%3 studies (3/-)56.7 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.